Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis.

NCT07874334 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT07874334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07874334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis.
Lead sponsor
Hadassah Medical Organization
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 15, 2026
Completion date
December 31, 2032
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

light-chain amyloidosis, relapsed/refractory multiple myeloma (rrmm)